Gyros and DI Biotech Sign Distribution Agreement for the Korean Market
Gyros AB (Uppsala, Sweden), a provider of automated micro-immunoassays for therapeutic protein development, has signed a distribution agreement with DI Biotech (Seoul, Korea), a supplier to the Korean life sciences market.
Gyros AB (Uppsala, Sweden), a provider of automated micro-immunoassays for therapeutic protein development, has signed a distribution agreement with DI Biotech (Seoul, Korea), a supplier to the Korean life sciences market. Under the terms of the agreement, DI Biotech will market and provide full support for Gyros’s proprietary technology, Gyrolab, to the Korean pharmaceutical, biotechnology, CRO, and CMO industries.
Gyrolab is Gyros’s automated and open platform, an analytical tool that reduces the time required to optimize and execute immunoassays. This reduction results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. Gyrolab enables assays to be conducted with a reduced background, four-log dynamic range, and with higher throughput, using only nanoliter volumes of critical reagents and sample.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
